Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    120

Stocks News & Analysis

stocks

ASX healthcare share undervalued post earnings

Short term headwinds mask long term value opportunity.
stocks

ASX energy share sees 363% increase in dividend

Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks

Wide moat share remains cheap despite rising costs

Higher costs weigh on profits but stronger sales trends support long term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,422.7029.400.31%
CAC 408,439.2013.81-0.16%
DAX 4026,266.14159.540.61%
Dow JONES (US)53,577.40160.240.30%
FTSE 10010,886.1631.840.29%
HKSE25,635.24124.140.49%
NASDAQ26,151.30171.110.66%
Nikkei 22565,538.17318.26-0.48%
NZX 50 Index14,029.4836.760.26%
S&P 5007,677.2824.420.32%
S&P/ASX 2009,214.5030.800.34%
SSE Composite Index3,889.240.20-0.01%

Market Movers